Aclaris Therapeutics, Inc.
- Aclaris Therapeutics Receives FDA Approval for Eskata (hydrogen peroxide) Topical Solution, 40% (w/w) for the Treatment of Raised Seborrheic Keratoses - December 17, 2017
- FDA Accepts Aclaris Therapeutics’ New Drug Application for Topical Treatment of Seborrheic Keratosis, a Common Skin Condition - May 9, 2017
- Aclaris Therapeutics Submits New Drug Application for A-101 as a Novel Treatment for Seborrheic Keratosis – a Common Skin Condition - February 27, 2017
Drugs Associated with Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc. manufactures, markets and/or distributes more than 2 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: hydrogen peroxide
Drug class: topical anti-infectives
|9 reviews||1.2 / 10|
Generic name: oxymetazoline
Drug class: topical anti-rosacea agents
|109 reviews||3.0 / 10|
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|